The clinical data update is strongly positive, showing deepening and durable efficacy with no safety concerns, and the fully dosed Embolden trial with overenrollment increases statistical power. The extended cash runway removes near-term financing risk. Monitor for topline Embolden data in 2H 2027 and PPQ completion by year-end 2026 as key catalysts.
Price Chart
Executive Summary
Neurogene reported Q2 2026 financial results, highlighting continued positive Phase 1/2 data for NGN-401 in Rett syndrome, with 100% of participants showing improvement and an average of 4.7 developmental milestones gained. The company completed dosing of 25 participants in the Embolden registrational trial (overenrolled by 25%), initiated its PPQ campaign for BLA submission, and extended its cash runway into Q1 2029 via a ~$144M oversubscribed follow-on offering. Net loss widened to $34.5M from $22.0M YoY, driven by increased R&D and G&A expenses including a one-time stock compensation catch-up charge. The stock will move on the strength of the clinical data update and the extended cash runway, which de-risks the path to the Embolden topline readout in 2H 2027.
Key Facts
- 100% of Phase 1/2 participants (N=10) improved on CGI-I and gained ≥1 developmental milestone; average 4.7 milestones per participant.
- 80% (8 of 10) met the Embolden composite responder definition at 12 months, exceeding the 35% minimum success threshold by 2.4x.
- Embolden registrational trial fully dosed with 25 participants (overenrolled by 25%); topline data expected 2H 2027.
- PPQ campaign initiated to support BLA submission; completion of PPQ runs expected by year-end 2026.
- Cash, cash equivalents, and short-term investments were $225.4M as of June 30, 2026; pro forma cash ~$360.2M after ~$134.8M net proceeds from July 2026 offering, extending runway into Q1 2029.
- Net loss for Q2 2026 was $34.5M, compared to $22.0M in Q2 2025.
- R&D expenses were $25.5M for Q2 2026, up from $19.4M in Q2 2025.
- G&A expenses were $11.2M for Q2 2026, up from $6.7M in Q2 2025, driven by a one-time stock compensation catch-up charge.
Financial Impact
Net loss widened by $12.5M YoY to $34.5M; cash runway extended into Q1 2029 via ~$144M gross follow-on offering.
Risk Factors
- Embolden topline data in 2H 2027 is the pivotal readout; Phase 1/2 data may not fully predict registrial results.
- Competition from other Rett syndrome gene therapy programs (e.g., Taysha Gene Therapies) could emerge.
- Manufacturing scale-up and regulatory approval risks remain for a first-in-class gene therapy.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001404644-26-000056 |
| Document: ngne_2qye26earningsrelease.htm | 0001404644-26-000056 |
| Document: ngne-20260811.htm | 0001404644-26-000056 |
| Document: 0001404644-26-000056-index-headers.html | 0001404644-26-000056 |
| Document: 0001404644-26-000056-index.html | 0001404644-26-000056 |
| Document: 0001404644-26-000056.txt | 0001404644-26-000056 |
| 8-K Data (Synthetic) | 0001404644-26-000056 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 19d ago | SC 13G | $25.87 | awaiting T+20 | — | $23.54 (−9.01%) |
Oct 6, 2026 20d ago | SC 13G | $25.45 | awaiting T+20 | — | $23.54 (−7.50%) |
Aug 11, 2026 10w ago | 8-K | $36.55 $37.88 | ▲ +3.64% | ▲ +4.70% | $23.54 (−35.60%) |
Jun 30, 2026 16w ago | 424B5 | $33.88 $33.66 | ▲ +0.65% | ▼ −1.54% | $23.54 (+30.52%) |
Jun 29, 2026 17w ago | 8-K | $32.28 $34.90 | ▲ +8.12% | ▲ +8.40% | $23.54 (−27.08%) |
Jun 8, 2026 20w ago | 8-K | $28.60 $32.56 | ▲ +13.85% | ▲ +12.21% | $23.54 (−17.69%) |
Apr 20, 2026 27w ago | 8-K | $27.74 $27.98 | ▲ +0.87% | ▼ −3.34% | $23.54 (−15.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers